Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transmission-based Precautions I: Contact, Enteric, and Droplets01:17

Transmission-based Precautions I: Contact, Enteric, and Droplets

3.6K
Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
3.6K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

175
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
175
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

169
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
169
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

120
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
120
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advance Care Planning, Race, and Age.

American journal of medical quality : the official journal of the American College of Medical Quality·2026
Same author

Hospitalists Caring for Behavioral Health Inpatients: A Hybrid Consultation Model.

Journal of general internal medicine·2025
Same author

Improving Antibiotic Stewardship for Inpatients with Reported Beta-Lactam Allergies and Limited Access to Penicillin Skin Testing.

Joint Commission journal on quality and patient safety·2022
Same author

The Virtual Hospitalist: a Critical Innovation During the COVID-19 Crisis.

Journal of general internal medicine·2021
Same author

Measuring Patient Preferences and Clinic Follow-Up Utilizing an Embedded Discharge Appointment Scheduler: A Pilot Study.

Joint Commission journal on quality and patient safety·2019
Same author

Air Pollution Still Kills.

The New England journal of medicine·2017
Same journal

Public Health Response to Clade Ib Mpox with Multiple Exposures in Congregate Living Settings - New Hampshire, February 2025.

NEJM evidence·2026
Same journal

Berberine-Ursodeoxycholate - Bringing Traditional Chinese Medicine to Our World.

NEJM evidence·2026
Same journal

Outbreak of Legionnaires' Disease Associated with Cooling Tower Systems in Central Harlem.

NEJM evidence·2026
Same journal

Immunotherapy for Fertility in Autoimmune Premature Ovarian Insufficiency.

NEJM evidence·2026
Same journal

A Randomized Trial of Interval Likelihood Ratios for Clinical Decision-Making.

NEJM evidence·2026
Same journal

Evidence for Evidence-Based Medicine - A Call for Some Theory and a New Problem.

NEJM evidence·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.2K

Does Prophylaxis Prevent Recurrent Clostridioides difficile Infection?

Rebecca E Berger1

  • 1Weill Cornell Medicine, New York.

NEJM Evidence
|February 6, 2024
PubMed
Summary
This summary is machine-generated.

This case study explores whether to use prophylaxis for recurrent Clostridioides difficile infection. It questions the need for preventative measures when treating a new infection with antibiotics like ceftriaxone.

More Related Videos

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
09:12

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

Published on: June 15, 2018

10.1K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.0K

Related Experiment Videos

Last Updated: Jul 4, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.2K
A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
09:12

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

Published on: June 15, 2018

10.1K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.0K

Area of Science:

  • Infectious Diseases
  • Clinical Medicine
  • Pharmacology

Background:

  • A 68-year-old woman with a history of Clostridioides difficile colitis, successfully treated with oral vancomycin.
  • The patient is now admitted for pyelonephritis, requiring intravenous ceftriaxone treatment.

Purpose of the Study:

  • To determine the necessity of prophylactic treatment against recurrent Clostridioides difficile infection.
  • To evaluate the risk of C. difficile recurrence when initiating broad-spectrum antibiotics after a recent episode.

Main Methods:

  • Case study analysis of a patient with a history of C. difficile colitis.
  • Review of clinical guidelines and evidence regarding antibiotic use and C. difficile prophylaxis.

Main Results:

  • The abstract does not contain results, it poses a clinical question.

Conclusions:

  • Further investigation is needed to establish optimal prophylactic strategies for patients at high risk of recurrent Clostridioides difficile infection.
  • Clinical decision-making should weigh the benefits of prophylaxis against potential risks and antibiotic stewardship principles.